Friday, January 15News That Matters

Tag: Myers

Bristol Myers Squibb buys biopharma firm MyoKardia for $13B

Latest
Oct. 5 (UPI) -- Bristol Myers Squibb acknowledged Monday this may possibly per chance well purchase biopharmaceutical firm MyoKardia for $13 billion, its 2d trim acquisition in two years. MyoKardia, which develops therapies for extreme cardiovascular diseases, produces mavacamten, a most likely remedy to handle the power coronary heart disease obstructive hypertrophic cardiomyopathy. "We are further strengthening our outstanding cardiovascular franchise by the addition of mavacamten, a promising remedy with the aptitude to handle a serious unmet clinical need in sufferers with cardiovascular disease," Bristol Myers Squibb CEO Dr. Giovanni Caforio acknowledged in an announcement. MykoKardia CEO Tassos Gianakakos acknowledged the firm became as soon as created eight years ago to handle ext...